What is thymosin alpha-1?
5 min read · Updated October 2026 · MY PEPTIDES Research Team
Key facts
Thymosin alpha-1 is a 28-amino-acid peptide originally characterised from thymic tissue extracts, where the thymus gland\u2019s role in immune development made its constituent peptides a natural research target. It is studied in immunology in the context of T-cell function and immune signalling. Three naming points cause persistent confusion: it is unrelated in sequence and function to thymosin beta-4, a separate peptide despite the shared family name; it is not the same as thymalin, which is a thymic peptide preparation associated with a different line of research; and it has been developed pharmaceutically under the international non-proprietary name thymalfasin, which is unusual for a compound in this market. Regulatory status differs by jurisdiction and it is not a licensed medicine for general use in the UK. MY PEPTIDES does not stock it. General information for laboratory context only, not medical advice.
The short answer
Thymosin alpha-1 is a 28-residue peptide characterised from thymic tissue extracts and studied in immunology, in the context of T-cell function and immune signalling.
It is also the centre of one of the worst naming tangles in this field. Three separate confusions attach to it, and sorting them out is most of what a reader needs.
Three things it is not
It is not thymosin beta-4. These share a family name and nothing else that matters. Different sequences, different lengths, different research literatures: alpha-1 sits in immunology, beta-4 sits in actin binding and tissue repair and is the parent of the fragment sold as TB-500. The "thymosin" label records that both were originally found in thymic extracts, which is a statement about where researchers were looking in the 1960s and 1970s rather than about the molecules themselves. Treating the alpha and beta thymosins as variants of one thing is simply an error.
It is not thymalin. Thymalin is a thymic peptide preparation from a different research programme, principally the Russian bioregulator work covered in our guide on peptide bioregulators. Similar name, similar tissue of origin, different compound and a very different evidence base.
It is not only a research compound. This is the unusual part, and it cuts the other way from most pages on this site.
The pharmaceutical history
Thymosin alpha-1 has an international non-proprietary name, thymalfasin. That detail is worth more than it looks.
An INN is not a laboratory code or a catalogue designation. It is allocated through a formal process as part of genuine pharmaceutical development, which means this compound progressed far beyond the preclinical stage where most research compounds stop. It has a history of pharmaceutical development and of regulatory authorisation in some jurisdictions.
That makes it a genuine outlier in a market where the typical compound has never been tested in a human at all. It also makes precision important in the other direction: approval in one jurisdiction is not approval everywhere, regulatory status changes, and it is not a licensed medicine for general use in the UK. Anyone who needs the current position for a particular country should check with that regulator rather than take it from any website, this one included.
What is actually studied
The research context is immune function, principally around T-cells and immune signalling, which follows naturally from the thymus being the organ where T-cells mature. As with any such compound, published observations depend on the model, the concentration, the exposure and the endpoint, and belong to the systems in which they were made.
Structurally, 28 residues is a moderate length: long enough that conformation may matter, short enough to synthesise and characterise reliably. Standard handling discipline applies, and our guide on storing research peptides covers it.
What the research does not establish
Research observations in cell and animal systems do not establish human outcomes, and the fact that a compound has pharmaceutical history in some jurisdiction does not license claims about it elsewhere. In the UK, supplying an unlicensed product for human medicinal use is unlawful under the Human Medicines Regulations 2012 regardless of its status abroad; our guide on whether peptides are legal in the UK covers the framework.
Where MY PEPTIDES stands
We do not stock thymosin alpha-1. There is no Certificate of Analysis for it in our library and no product page for it on this site, and this guide is not an offer to supply it. What we do supply, and the documentation standard we hold it to, is set out in our guide on certificates of analysis.
The bottom line
Thymosin alpha-1 is a 28-residue immunology research peptide, unrelated to thymosin beta-4 despite the name, distinct from thymalin, and unusual in this field for having real pharmaceutical development behind it under the name thymalfasin. Its regulatory status varies by jurisdiction and it is not licensed for general use in the UK. We do not supply it.
All compounds referenced on this site are discussed strictly in the context of in-vitro laboratory research. Nothing here is a medicine, a supplement or a therapeutic product, nothing here describes administration to humans or animals, and this guide is general information rather than medical, legal or research advice.
Frequently asked questions
- What is thymosin alpha-1?
- A peptide of 28 amino acids originally characterised from extracts of thymic tissue. The thymus is where T-cells mature, so peptides found in thymic extracts were an obvious place to look for molecules involved in immune development, and thymosin alpha-1 emerged from that work. In research it is studied in the context of T-cell function and immune signalling.
- Is thymosin alpha-1 the same as thymosin beta-4?
- No, and the shared name is misleading. They are different peptides with different sequences, different lengths and different research contexts: thymosin alpha-1 is studied in immunology, while thymosin beta-4 is studied in relation to actin binding and tissue repair, and is the parent molecule of the fragment sold as TB-500. The "thymosin" label reflects where these peptides were originally found rather than any structural or functional relationship. Our guide on [TB-500](/guides/what-is-tb-500) covers the beta-4 side.
- Is thymalin the same thing?
- No. Thymalin is a thymic peptide preparation associated with a separate line of research, principally the Russian bioregulator programme, rather than a synonym for thymosin alpha-1. The two are frequently conflated because both derive from thymic tissue and the names are similar. Our guide on [peptide bioregulators](/guides/what-are-peptide-bioregulators) covers that programme and the caveats attached to its evidence base.
- What is thymalfasin?
- It is the international non-proprietary name assigned to thymosin alpha-1 for pharmaceutical use. Encountering a research compound with an INN is notable, because an INN is allocated as part of genuine pharmaceutical development rather than being a laboratory code. It indicates the compound progressed considerably further than most of what is discussed under the research heading.
- Is thymosin alpha-1 an approved medicine?
- Its regulatory status differs between jurisdictions, and it has a history of pharmaceutical development and authorisation in some countries, which genuinely distinguishes it from most compounds in this market. It is not a licensed medicine for general use in the UK, and anyone who needs to know the current position for a specific jurisdiction should check with that regulator rather than relying on a guide. Material sold for research is supplied for in-vitro laboratory use only.
- Do you sell thymosin alpha-1?
- No. We do not stock it and there is no Certificate of Analysis for it in our library. It is documented here largely because the naming confusion around the thymosins is severe enough to be worth untangling.